X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4012) 4012
Publication (275) 275
Book Review (53) 53
Magazine Article (10) 10
Book Chapter (6) 6
Conference Proceeding (6) 6
Newspaper Article (5) 5
Book / eBook (2) 2
Dissertation (2) 2
Newsletter (2) 2
Web Resource (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3542) 3542
female (3528) 3528
middle aged (1684) 1684
oncology (1654) 1654
ovarian neoplasms - drug therapy (1468) 1468
adult (1451) 1451
index medicus (1426) 1426
aged (1151) 1151
ovarian cancer (1001) 1001
cancer (972) 972
animals (888) 888
chemotherapy (824) 824
ovarian neoplasms - chemically induced (707) 707
male (654) 654
antineoplastic combined chemotherapy protocols - adverse effects (641) 641
ovarian neoplasms - pathology (613) 613
ovarian-cancer (559) 559
antineoplastic combined chemotherapy protocols - therapeutic use (539) 539
antineoplastic agents - adverse effects (538) 538
obstetrics & gynecology (530) 530
risk factors (487) 487
mice (461) 461
breast neoplasms - drug therapy (429) 429
breast cancer (410) 410
cisplatin (367) 367
research (355) 355
breast-cancer (349) 349
carcinoma (334) 334
tumors (332) 332
cisplatin - adverse effects (331) 331
treatment outcome (327) 327
paclitaxel (323) 323
care and treatment (321) 321
neoplasms - drug therapy (314) 314
cell line, tumor (313) 313
cisplatin - administration & dosage (303) 303
drug administration schedule (303) 303
health aspects (296) 296
antineoplastic agents - therapeutic use (295) 295
neutropenia - chemically induced (287) 287
paclitaxel - administration & dosage (287) 287
pharmacology & pharmacy (283) 283
risk (277) 277
rats (270) 270
paclitaxel - adverse effects (264) 264
carboplatin - administration & dosage (262) 262
pregnancy (252) 252
time factors (252) 252
dose-response relationship, drug (250) 250
thrombocytopenia - chemically induced (242) 242
women (241) 241
carboplatin - adverse effects (238) 238
therapy (233) 233
apoptosis (228) 228
carboplatin (228) 228
aged, 80 and over (225) 225
expression (217) 217
analysis (209) 209
retrospective studies (208) 208
ovarian neoplasms - metabolism (203) 203
breast neoplasms - chemically induced (202) 202
nausea - chemically induced (196) 196
adolescent (195) 195
antineoplastic agents - administration & dosage (191) 191
medicine & public health (190) 190
ovarian neoplasms - epidemiology (190) 190
prognosis (189) 189
ovarian neoplasms - genetics (185) 185
prospective studies (182) 182
vomiting - chemically induced (181) 181
neoplasm staging (180) 180
article (177) 177
leukopenia - chemically induced (177) 177
cancer therapies (174) 174
toxicity (171) 171
trial (169) 169
follow-up studies (166) 166
research article (165) 165
cyclophosphamide (164) 164
antineoplastic combined chemotherapy protocols - administration & dosage (163) 163
metastasis (162) 162
gene expression (157) 157
hematology, oncology and palliative medicine (157) 157
case-control studies (154) 154
medicine (154) 154
lung neoplasms - drug therapy (152) 152
obstetrics and gynecology (152) 152
proteins (151) 151
cohort studies (146) 146
primary ovarian insufficiency - chemically induced (146) 146
oncology, experimental (144) 144
ovarian neoplasms - surgery (144) 144
antineoplastic agents - pharmacology (142) 142
cyclophosphamide - administration & dosage (142) 142
drug therapy (142) 142
menopause (142) 142
doxorubicin - administration & dosage (141) 141
cyclophosphamide - adverse effects (140) 140
incidence (139) 139
disease-free survival (137) 137
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3740) 3740
Japanese (102) 102
German (66) 66
French (59) 59
Russian (44) 44
Chinese (16) 16
Spanish (12) 12
Dutch (11) 11
Italian (10) 10
Polish (10) 10
Czech (6) 6
Hungarian (6) 6
Bulgarian (3) 3
Norwegian (3) 3
Portuguese (3) 3
Danish (2) 2
Serbian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Croatian (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 60 - 68
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose‐escalation... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | THERAPEUTICS | FARLETUZUMAB | PLATINUM-RESISTANT OVARIAN | MONOCLONAL-ANTIBODY | COMBINATION | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | DELIVERY | THERAPY | ONCOLOGY | PROTEINS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 146, Issue 2, pp. 386 - 391
Abstract Objectives Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease.... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Peripheral Nervous System Diseases - chemically induced | Diarrhea - psychology | Nausea - chemically induced | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Fatigue - chemically induced | Pain - chemically induced | Diarrhea - chemically induced | Arthralgia - chemically induced | Gastroesophageal Reflux - chemically induced | Nausea - psychology | Alopecia - psychology | Young Adult | Constipation - psychology | Patient Care Planning | Sexual Dysfunction, Physiological - psychology | Antineoplastic Agents - adverse effects | Adult | Female | Surveys and Questionnaires | Neoplasm Recurrence, Local - psychology | Survivors - psychology | Gastroesophageal Reflux - psychology | Ovarian Neoplasms - drug therapy | Arthralgia - psychology | Ovarian Neoplasms - psychology | Memory Disorders - psychology | Attitude to Health | Peripheral Nervous System Diseases - psychology | Fatigue - psychology | Sexual Dysfunction, Physiological - chemically induced | Drug-Related Side Effects and Adverse Reactions - etiology | Hospitalization | Remission Induction | Constipation - chemically induced | Vomiting - chemically induced | Pain - psychology | Adolescent | Vomiting - psychology | Quality of Life | Alopecia - chemically induced | Aged | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - psychology | Memory Disorders - chemically induced | Complications and side effects | Ovarian cancer | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 10, pp. 1112 - 1118
Journal Article
Archives of Toxicology, ISSN 0340-5761, 6/2012, Volume 86, Issue 6, pp. 975 - 982
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 09/2017, Volume 146, Issue 3, pp. 484 - 490
Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme... 
Epacadostat | IDO1 enzyme inhibitor | Tamoxifen | Ca-125 | Ovarian cancer | SURVIVAL | DIAGNOSIS | PROTEIN | PROGNOSIS | INDOLEAMINE 2,3-DIOXYGENASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | IMMUNOTHERAPY | EXPRESSION | T-CELLS | Recurrence | Neoplasms, Glandular and Epithelial - chemistry | Oximes - pharmacokinetics | Oximes - adverse effects | Peritoneal Neoplasms - blood | Humans | Middle Aged | Oximes - therapeutic use | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Peritoneal Neoplasms - chemistry | Antineoplastic Agents, Hormonal - adverse effects | Early Termination of Clinical Trials | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - chemistry | Exanthema - chemically induced | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovarian Neoplasms - drug therapy | Pruritus - chemically induced | Fallopian Tube Neoplasms - drug therapy | Drug Eruptions - etiology | Ovarian Neoplasms - chemistry | CA-125 Antigen - blood | Indoleamine-Pyrrole 2,3,-Dioxygenase - analysis | Ovarian Neoplasms - blood | Survival Rate | Sulfonamides - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Tamoxifen - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Sulfonamides - adverse effects | Aged | Tamoxifen - adverse effects | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Care and treatment | Chemotherapy | Enzyme inhibitors | Cancer | Medical research | Medicine, Experimental
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1697 - 1708
Journal Article